Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RVTY 
Revvity Inc. (RVTY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/07/2025: RVTY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $113.67
1 Year Target Price $113.67
| 10 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.58% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/07/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.29B USD | Price to earnings Ratio 46.79 | 1Y Target Price 113.67 |
Price to earnings Ratio 46.79 | 1Y Target Price 113.67 | ||
Volume (30-day avg) 19 | Beta 1.07 | 52 Weeks Range 81.30 - 128.00 | Updated Date 11/10/2025 |
52 Weeks Range 81.30 - 128.00 | Updated Date 11/10/2025 | ||
Dividends yield (FY) 0.31% | Basic EPS (TTM) 1.94 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-10-27 | When Before Market | Estimate 0.5 | Actual 0.4 |
Profitability
Profit Margin 8.44% | Operating Margin (TTM) 13.79% |
Management Effectiveness
Return on Assets (TTM) 2.09% | Return on Equity (TTM) 3.04% |
Valuation
Trailing PE 46.79 | Forward PE 16.72 | Enterprise Value 12999008166 | Price to Sales(TTM) 3.66 |
Enterprise Value 12999008166 | Price to Sales(TTM) 3.66 | ||
Enterprise Value to Revenue 4.64 | Enterprise Value to EBITDA 15.82 | Shares Outstanding 113375621 | Shares Floating 105897365 |
Shares Outstanding 113375621 | Shares Floating 105897365 | ||
Percent Insiders 0.34 | Percent Institutions 102.88 |
Upturn AI SWOT
Revvity Inc.
Company Overview
History and Background
Revvity Inc., formerly PerkinElmer, was founded in 1931. Initially focused on optical instruments, it evolved into a global leader in life sciences and diagnostics, undergoing a rebranding to Revvity in 2023 to reflect its expanded focus.
Core Business Areas
- Life Sciences: Provides reagents, instruments, and software for drug discovery, research, and bioproduction.
- Diagnostics: Offers screening solutions for newborns and prenatal health, as well as diagnostic tools for various diseases.
Leadership and Structure
Prahlad Singh is the CEO. The company has a hierarchical organizational structure with various business units and functional departments.
Top Products and Market Share
Key Offerings
- Victor Nivo Multimode Microplate Reader: A high-performance microplate reader used in various research applications. Market share is significant in the high-throughput screening market. Competitors include Thermo Fisher Scientific and Bio-Rad Laboratories.
- DELFIA Assays: A suite of immunoassays for drug discovery and diagnostics. Strong presence in the immunoassay market, specifically for high sensitivity applications. Competitors include Roche and Siemens Healthineers.
Market Dynamics
Industry Overview
The life sciences and diagnostics industry is experiencing significant growth, driven by advances in genomics, proteomics, and personalized medicine. It is a highly competitive space with constant innovation.
Positioning
Revvity Inc. holds a strong position in both the life sciences and diagnostics markets, leveraging its diversified product portfolio and established customer base. Its competitive advantages include its broad technology platform and global reach.
Total Addressable Market (TAM)
The total addressable market for life sciences and diagnostics is estimated to be in the hundreds of billions of dollars. Revvity is well positioned to capture a significant portion of this TAM through its various divisions and product offerings.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global presence
- Strong brand recognition
- Innovation in life sciences and diagnostics
- Experienced leadership team
Weaknesses
- Integration challenges from acquisitions
- Dependence on R&D investment
- Exposure to regulatory changes
- Complex organizational structure
Opportunities
- Expansion into emerging markets
- Development of new diagnostic tests
- Growth in personalized medicine
- Strategic partnerships and collaborations
- Increased investment in life sciences research
Threats
- Intense competition
- Technological obsolescence
- Economic downturns
- Patent disputes
- Pricing pressures
Competitors and Market Share
Key Competitors
- TMO
- DHR
- WAT
Competitive Landscape
Revvity faces intense competition from larger, well-established players. Its advantages lie in its focused approach, innovative technologies, and specialized solutions.
Major Acquisitions
BioLegend
- Year: 2021
- Acquisition Price (USD millions): 5250
- Strategic Rationale: Expanded Revvityu2019s capabilities in antibody-based research reagents and cell analysis.
Growth Trajectory and Initiatives
Historical Growth: Historically, Revvity has grown through organic innovation and strategic acquisitions in the life sciences and diagnostics sectors.
Future Projections: Future growth is expected to be driven by continued expansion in key markets, the launch of new products, and strategic partnerships. Analyst estimates vary, but the overall outlook is positive.
Recent Initiatives: Recent initiatives include the rebranding to Revvity, focusing on innovation and new product development in personalized medicine and bioproduction.
Summary
Revvity (RVTY) is a well-established player in life sciences and diagnostics with a diversified product portfolio and global reach. The rebranding as Revvity signals a renewed focus on innovation. Intense competition and integration challenges pose potential hurdles. Continued investment in R&D and strategic acquisitions will be crucial for sustaining growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Revvity Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change rapidly. Conduct thorough research before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revvity Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1983-04-06 | CEO, President & Director Dr. Prahlad R. Singh Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.revvity.com |
Full time employees 11000 | Website https://www.revvity.com | ||
Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.